Vaccines, Conjugate: Semisynthetic vaccines consisting of polysaccharide antigens from microorganisms attached to protein carrier molecules. The carrier protein is recognized by macrophages and T-cells thus enhancing immunity. Conjugate vaccines induce antibody formation in people not responsive to polysaccharide alone, induce higher levels of antibody, and show a booster response on repeated injection.Pneumococcal Vaccines: Vaccines or candidate vaccines used to prevent infections with STREPTOCOCCUS PNEUMONIAE.Vaccines: Suspensions of killed or attenuated microorganisms (bacteria, viruses, fungi, protozoa), antigenic proteins, synthetic constructs, or other bio-molecular derivatives, administered for the prevention, amelioration, or treatment of infectious and other diseases.Vaccines, Inactivated: Vaccines in which the infectious microbial nucleic acid components have been destroyed by chemical or physical treatment (e.g., formalin, beta-propiolactone, gamma radiation) without affecting the antigenicity or immunogenicity of the viral coat or bacterial outer membrane proteins.Viral Vaccines: Suspensions of attenuated or killed viruses administered for the prevention or treatment of infectious viral disease.Vaccines, Combined: Two or more vaccines in a single dosage form.Vaccines, DNA: Recombinant DNA vectors encoding antigens administered for the prevention or treatment of disease. The host cells take up the DNA, express the antigen, and present it to the immune system in a manner similar to that which would occur during natural infection. This induces humoral and cellular immune responses against the encoded antigens. The vector is called naked DNA because there is no need for complex formulations or delivery agents; the plasmid is injected in saline or other buffers.Vaccines, Synthetic: Small synthetic peptides that mimic surface antigens of pathogens and are immunogenic, or vaccines manufactured with the aid of recombinant DNA techniques. The latter vaccines may also be whole viruses whose nucleic acids have been modified.Bacterial Vaccines: Suspensions of attenuated or killed bacteria administered for the prevention or treatment of infectious bacterial disease.AIDS Vaccines: Vaccines or candidate vaccines containing inactivated HIV or some of its component antigens and designed to prevent or treat AIDS. Some vaccines containing antigens are recombinantly produced.Vaccines, Subunit: Vaccines consisting of one or more antigens that stimulate a strong immune response. They are purified from microorganisms or produced by recombinant DNA techniques, or they can be chemically synthesized peptides.Vaccination: Administration of vaccines to stimulate the host's immune response. This includes any preparation intended for active immunological prophylaxis.Malaria Vaccines: Vaccines made from antigens arising from any of the four strains of Plasmodium which cause malaria in humans, or from P. berghei which causes malaria in rodents.Papillomavirus Vaccines: Vaccines or candidate vaccines used to prevent PAPILLOMAVIRUS INFECTIONS. Human vaccines are intended to reduce the incidence of UTERINE CERVICAL NEOPLASMS, so they are sometimes considered a type of CANCER VACCINES. They are often composed of CAPSID PROTEINS, especially L1 protein, from various types of ALPHAPAPILLOMAVIRUS.Meningococcal Vaccines: Vaccines or candidate vaccines used to prevent infection with NEISSERIA MENINGITIDIS.Hepatitis B Vaccines: Vaccines or candidate vaccines containing inactivated hepatitis B or some of its component antigens and designed to prevent hepatitis B. Some vaccines may be recombinantly produced.Measles Vaccine: A live attenuated virus vaccine of chick embryo origin, used for routine immunization of children and for immunization of adolescents and adults who have not had measles or been immunized with live measles vaccine and have no serum antibodies against measles. Children are usually immunized with measles-mumps-rubella combination vaccine. (From Dorland, 28th ed)Pertussis Vaccine: A suspension of killed Bordetella pertussis organisms, used for immunization against pertussis (WHOOPING COUGH). It is generally used in a mixture with diphtheria and tetanus toxoids (DTP). There is an acellular pertussis vaccine prepared from the purified antigenic components of Bordetella pertussis, which causes fewer adverse reactions than whole-cell vaccine and, like the whole-cell vaccine, is generally used in a mixture with diphtheria and tetanus toxoids. (From Dorland, 28th ed)Haemophilus Vaccines: Vaccines or candidate vaccines containing antigenic polysaccharides from Haemophilus influenzae and designed to prevent infection. The vaccine can contain the polysaccharides alone or more frequently polysaccharides conjugated to carrier molecules. It is also seen as a combined vaccine with diphtheria-tetanus-pertussis vaccine.BCG Vaccine: An active immunizing agent and a viable avirulent attenuated strain of Mycobacterium tuberculosis, var. bovis, which confers immunity to mycobacterial infections. It is used also in immunotherapy of neoplasms due to its stimulation of antibodies and non-specific immunity.Poliovirus Vaccine, Inactivated: A suspension of formalin-inactivated poliovirus grown in monkey kidney cell tissue culture and used to prevent POLIOMYELITIS.Rabies Vaccines: Vaccines or candidate vaccines used to prevent and treat RABIES. The inactivated virus vaccine is used for preexposure immunization to persons at high risk of exposure, and in conjunction with rabies immunoglobulin, for postexposure prophylaxis.Rotavirus Vaccines: Vaccines or candidate vaccines used to prevent infection with ROTAVIRUS.Cholera Vaccines: Vaccines or candidate vaccines used to prevent infection with VIBRIO CHOLERAE. The original cholera vaccine consisted of killed bacteria, but other kinds of vaccines now exist.Typhoid-Paratyphoid Vaccines: Vaccines used to prevent TYPHOID FEVER and/or PARATYPHOID FEVER which are caused by various species of SALMONELLA. Attenuated, subunit, and inactivated forms of the vaccines exist.Smallpox Vaccine: A live VACCINIA VIRUS vaccine of calf lymph or chick embryo origin, used for immunization against smallpox. It is now recommended only for laboratory workers exposed to smallpox virus. Certain countries continue to vaccinate those in the military service. Complications that result from smallpox vaccination include vaccinia, secondary bacterial infections, and encephalomyelitis. (Dorland, 28th ed)Tuberculosis Vaccines: Vaccines or candidate vaccines used to prevent or treat TUBERCULOSIS.Antibodies, Viral: Immunoglobulins produced in response to VIRAL ANTIGENS.Chickenpox Vaccine: A live, attenuated varicella virus vaccine used for immunization against chickenpox. It is recommended for children between the ages of 12 months and 13 years.Diphtheria-Tetanus-Pertussis Vaccine: A vaccine consisting of DIPHTHERIA TOXOID; TETANUS TOXOID; and whole-cell PERTUSSIS VACCINE. The vaccine protects against diphtheria, tetanus, and whooping cough.Mumps Vaccine: Vaccines used to prevent infection by MUMPS VIRUS. Best known is the live attenuated virus vaccine of chick embryo origin, used for routine immunization of children and for immunization of adolescents and adults who have not had mumps or been immunized with live mumps vaccine. Children are usually immunized with measles-mumps-rubella combination vaccine.Hepatitis A Vaccines: Vaccines or candidate vaccines used to prevent infection with hepatitis A virus (HEPATOVIRUS).Immunization Schedule: Schedule giving optimum times usually for primary and/or secondary immunization.Adjuvants, Immunologic: Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity.Immunization, Secondary: Any immunization following a primary immunization and involving exposure to the same or a closely related antigen.Measles-Mumps-Rubella Vaccine: A combined vaccine used to prevent MEASLES; MUMPS; and RUBELLA.Streptococcal Vaccines: Vaccines or candidate vaccines used to prevent STREPTOCOCCAL INFECTIONS.Anthrax Vaccines: Vaccines or candidate vaccines used to prevent ANTHRAX.Dengue Vaccines: Vaccines or candidate vaccines used to prevent infection with DENGUE VIRUS. These include live-attenuated, subunit, DNA, and inactivated vaccines.Vaccines, Virosome: Vaccines using VIROSOMES as the antigen delivery system that stimulates the desired immune response.Immunization: Deliberate stimulation of the host's immune response. ACTIVE IMMUNIZATION involves administration of ANTIGENS or IMMUNOLOGIC ADJUVANTS. PASSIVE IMMUNIZATION involves administration of IMMUNE SERA or LYMPHOCYTES or their extracts (e.g., transfer factor, immune RNA) or transplantation of immunocompetent cell producing tissue (thymus or bone marrow).Viral Hepatitis Vaccines: Any vaccine raised against any virus or viral derivative that causes hepatitis.Poliovirus Vaccine, Oral: A live vaccine containing attenuated poliovirus, types I, II, and III, grown in monkey kidney cell tissue culture, used for routine immunization of children against polio. This vaccine induces long-lasting intestinal and humoral immunity. Killed vaccine induces only humoral immunity. Oral poliovirus vaccine should not be administered to immunocompromised individuals or their household contacts. (Dorland, 28th ed)Yellow Fever Vaccine: Vaccine used to prevent YELLOW FEVER. It consists of a live attenuated 17D strain of the YELLOW FEVER VIRUS.Antibodies, Bacterial: Immunoglobulins produced in a response to BACTERIAL ANTIGENS.Plague Vaccine: A suspension of killed Yersinia pestis used for immunizing people in enzootic plague areas.Fungal Vaccines: Suspensions of attenuated or killed fungi administered for the prevention or treatment of infectious fungal disease.Rubella Vaccine: A live attenuated virus vaccine of duck embryo or human diploid cell tissue culture origin, used for routine immunization of children and for immunization of nonpregnant adolescent and adult females of childbearing age who are unimmunized and do not have serum antibodies to rubella. Children are usually immunized with measles-mumps-rubella combination vaccine. (Dorland, 28th ed)Vaccines, Acellular: Vaccines that are produced by using only the antigenic part of the disease causing organism. They often require a "booster" every few years to maintain their effectiveness.SAIDS Vaccines: Vaccines or candidate vaccines designed to prevent SAIDS; (SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME); and containing inactivated SIMIAN IMMUNODEFICIENCY VIRUS or type D retroviruses or some of their component antigens.Salmonella Vaccines: Vaccines or candidate vaccines used to prevent infection with SALMONELLA. This includes vaccines used to prevent TYPHOID FEVER or PARATYPHOID FEVER; (TYPHOID-PARATYPHOID VACCINES), and vaccines used to prevent nontyphoid salmonellosis.Vaccines, Virus-Like Particle: Vaccines using supra-molecular structures composed of multiple copies of recombinantly expressed viral structural proteins. They are often antigentically indistinguishable from the virus from which they were derived.Mice, Inbred BALB CEbola Vaccines: Vaccines or candidate vaccines used to prevent EBOLA HEMORRHAGIC FEVER.Influenza, Human: An acute viral infection in humans involving the respiratory tract. It is marked by inflammation of the NASAL MUCOSA; the PHARYNX; and conjunctiva, and by headache and severe, often generalized, myalgia.Antibodies, Neutralizing: Antibodies that reduce or abolish some biological activity of a soluble antigen or infectious agent, usually a virus.Staphylococcal VaccinesDiphtheria-Tetanus-acellular Pertussis Vaccines: Combined vaccines consisting of DIPHTHERIA TOXOID; TETANUS TOXOID; and an acellular form of PERTUSSIS VACCINE. At least five different purified antigens of B. pertussis have been used in various combinations in these vaccines.Cytomegalovirus Vaccines: Vaccines or candidate vaccines used to prevent infection with CYTOMEGALOVIRUS.Immunization Programs: Organized services to administer immunization procedures in the prevention of various diseases. The programs are made available over a wide range of sites: schools, hospitals, public health agencies, voluntary health agencies, etc. They are administered to an equally wide range of population groups or on various administrative levels: community, municipal, state, national, international.Injections, Intramuscular: Forceful administration into a muscle of liquid medication, nutrient, or other fluid through a hollow needle piercing the muscle and any tissue covering it.Diphtheria-Tetanus Vaccine: A combined vaccine used to prevent infection with diphtheria and tetanus toxoid. This is used in place of DTP vaccine (DIPHTHERIA-TETANUS-PERTUSSIS VACCINE) when PERTUSSIS VACCINE is contraindicated.Poliovirus Vaccines: Vaccines used to prevent POLIOMYELITIS. They include inactivated (POLIOVIRUS VACCINE, INACTIVATED) and oral vaccines (POLIOVIRUS VACCINE, ORAL).Administration, Intranasal: Delivery of medications through the nasal mucosa.Escherichia coli Vaccines: Vaccines or candidate vaccines used to prevent or treat both enterotoxigenic and enteropathogenic Escherichia coli infections.Immunoglobulin G: The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B.West Nile Virus Vaccines: Vaccines or candidate vaccines used to prevent infection with WEST NILE VIRUS.Hemagglutination Inhibition Tests: Serologic tests in which a known quantity of antigen is added to the serum prior to the addition of a red cell suspension. Reaction result is expressed as the smallest amount of antigen which causes complete inhibition of hemagglutination.Shigella Vaccines: Vaccines or candidate vaccines used to prevent bacillary dysentery (DYSENTERY, BACILLARY) caused by species of SHIGELLA.Neutralization Tests: The measurement of infection-blocking titer of ANTISERA by testing a series of dilutions for a given virus-antiserum interaction end-point, which is generally the dilution at which tissue cultures inoculated with the serum-virus mixtures demonstrate cytopathology (CPE) or the dilution at which 50% of test animals injected with serum-virus mixtures show infectivity (ID50) or die (LD50).Antibody Formation: The production of ANTIBODIES by proliferating and differentiated B-LYMPHOCYTES under stimulation by ANTIGENS.Herpes Zoster Vaccine: An attenuated vaccine used to prevent and/or treat HERPES ZOSTER, a disease caused by HUMAN HERPESVIRUS 3.Polysorbates: Sorbitan mono-9-octadecanoate poly(oxy-1,2-ethanediyl) derivatives; complex mixtures of polyoxyethylene ethers used as emulsifiers or dispersing agents in pharmaceuticals.Immunity, Humoral: Antibody-mediated immune response. Humoral immunity is brought about by ANTIBODY FORMATION, resulting from TH2 CELLS activating B-LYMPHOCYTES, followed by COMPLEMENT ACTIVATION.Brucella Vaccine: A bacterial vaccine for the prevention of brucellosis in man and animal. Brucella abortus vaccine is used for the immunization of cattle, sheep, and goats.Tetanus ToxoidHerpesvirus Vaccines: Vaccines or candidate vaccines used to prevent infection by any virus from the family HERPESVIRIDAE.Injections, Intradermal: The forcing into the skin of liquid medication, nutrient, or other fluid through a hollow needle, piercing the top skin layer.Leishmaniasis Vaccines: Vaccines or candidate vaccines used to prevent infection with LEISHMANIA.Aluminum Hydroxide: A compound with many biomedical applications: as a gastric antacid, an antiperspirant, in dentifrices, as an emulsifier, as an adjuvant in bacterins and vaccines, in water purification, etc.Influenza A Virus, H1N1 Subtype: A subtype of INFLUENZA A VIRUS with the surface proteins hemagglutinin 1 and neuraminidase 1. The H1N1 subtype was responsible for the Spanish flu pandemic of 1918.Alum Compounds: Aluminum metal sulfate compounds used medically as astringents and for many industrial purposes. They are used in veterinary medicine for the treatment of ulcerative stomatitis, leukorrhea, conjunctivitis, pharyngitis, metritis, and minor wounds.Herpes Simplex Virus Vaccines: Vaccines or candidate vaccines used to prevent infection with viruses from the genus SIMPLEXVIRUS. This includes vaccines for HSV-1 and HSV-2.Antigens, Bacterial: Substances elaborated by bacteria that have antigenic activity.Diphtheria Toxoid: The formaldehyde-inactivated toxin of Corynebacterium diphtheriae. It is generally used in mixtures with TETANUS TOXOID and PERTUSSIS VACCINE; (DTP); or with tetanus toxoid alone (DT for pediatric use and Td, which contains 5- to 10-fold less diphtheria toxoid, for other use). Diphtheria toxoid is used for the prevention of diphtheria; DIPHTHERIA ANTITOXIN is for treatment.SqualeneRespiratory Syncytial Virus Vaccines: Vaccines or candidate vaccines used to prevent infection with RESPIRATORY SYNCYTIAL VIRUSES.Cross Protection: Protection conferred on a host by inoculation with one strain or component of a microorganism that prevents infection when later challenged with a similar strain. Most commonly the microorganism is a virus.Japanese Encephalitis Vaccines: Vaccines or candidate vaccines used to prevent infection with Japanese B encephalitis virus (ENCEPHALITIS VIRUS, JAPANESE).Mass Vaccination: Administration of a vaccine to large populations in order to elicit IMMUNITY.Vaccines, Contraceptive: Vaccines or candidate vaccines used to prevent conception.CD8-Positive T-Lymphocytes: A critical subpopulation of regulatory T-lymphocytes involved in MHC Class I-restricted interactions. They include both cytotoxic T-lymphocytes (T-LYMPHOCYTES, CYTOTOXIC) and CD8+ suppressor T-lymphocytes.Genetic Vectors: DNA molecules capable of autonomous replication within a host cell and into which other DNA sequences can be inserted and thus amplified. Many are derived from PLASMIDS; BACTERIOPHAGES; or VIRUSES. They are used for transporting foreign genes into recipient cells. Genetic vectors possess a functional replicator site and contain GENETIC MARKERS to facilitate their selective recognition.Vaccines, Edible: Vaccines or candidate vaccines derived from edible plants. Transgenic plants (PLANTS, TRANSGENIC) are used as recombinant protein production systems and the edible plant tissue functions as an oral vaccine.Enzyme-Linked Immunosorbent Assay: An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed.Immunity, Cellular: Manifestations of the immune response which are mediated by antigen-sensitized T-lymphocytes via lymphokines or direct cytotoxicity. This takes place in the absence of circulating antibody or where antibody plays a subordinate role.Whooping Cough: A respiratory infection caused by BORDETELLA PERTUSSIS and characterized by paroxysmal coughing ending in a prolonged crowing intake of breath.Immunotherapy, Active: Active immunization where vaccine is administered for therapeutic or preventive purposes. This can include administration of immunopotentiating agents such as BCG vaccine and Corynebacterium parvum as well as biological response modifiers such as interferons, interleukins, and colony-stimulating factors in order to directly stimulate the immune system.Antigens, Protozoan: Any part or derivative of any protozoan that elicits immunity; malaria (Plasmodium) and trypanosome antigens are presently the most frequently encountered.Vaccine Potency: The relationship between an elicited ADAPTIVE IMMUNE RESPONSE and the dose of the vaccine administered.Cross Reactions: Serological reactions in which an antiserum against one antigen reacts with a non-identical but closely related antigen.Measles: A highly contagious infectious disease caused by MORBILLIVIRUS, common among children but also seen in the nonimmune of any age, in which the virus enters the respiratory tract via droplet nuclei and multiplies in the epithelial cells, spreading throughout the MONONUCLEAR PHAGOCYTE SYSTEM.Rickettsial Vaccines: Vaccines for the prevention of diseases caused by various species of Rickettsia.Smallpox: An acute, highly contagious, often fatal infectious disease caused by an orthopoxvirus characterized by a biphasic febrile course and distinctive progressive skin eruptions. Vaccination has succeeded in eradicating smallpox worldwide. (Dorland, 28th ed)Molecular Sequence Data: Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.Interferon-gamma: The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES.Parainfluenza Vaccines: Vaccines or candidate vaccines used to prevent infection with parainfluenza viruses in humans and animals.Immunity, Mucosal: Nonsusceptibility to the pathogenic effects of foreign microorganisms or antigenic substances as a result of antibody secretions of the mucous membranes. Mucosal epithelia in the gastrointestinal, respiratory, and reproductive tracts produce a form of IgA (IMMUNOGLOBULIN A, SECRETORY) that serves to protect these ports of entry into the body.Rotavirus Infections: Infection with any of the rotaviruses. Specific infections include human infantile diarrhea, neonatal calf diarrhea, and epidemic diarrhea of infant mice.Influenza A Virus, H5N1 Subtype: A subtype of INFLUENZA A VIRUS comprised of the surface proteins hemagglutinin 5 and neuraminidase 1. The H5N1 subtype, frequently referred to as the bird flu virus, is endemic in wild birds and very contagious among both domestic (POULTRY) and wild birds. It does not usually infect humans, but some cases have been reported.Influenza A Virus, H3N2 Subtype: A subtype of INFLUENZA A VIRUS comprised of the surface proteins hemagglutinin 3 and neuraminidase 2. The H3N2 subtype was responsible for the Hong Kong flu pandemic of 1968.Mice, Inbred C57BLInfluenza B virus: Species of the genus INFLUENZAVIRUS B that cause HUMAN INFLUENZA and other diseases primarily in humans. Antigenic variation is less extensive than in type A viruses (INFLUENZA A VIRUS) and consequently there is no basis for distinct subtypes or variants. Epidemics are less likely than with INFLUENZA A VIRUS and there have been no pandemics. Previously only found in humans, Influenza B virus has been isolated from seals which may constitute the animal reservoir from which humans are exposed.Pseudorabies Vaccines: Vaccines or candidate vaccines used to prevent PSEUDORABIES (Aujeszky's disease), a herpesvirus of swine and other animals.Macaca mulatta: A species of the genus MACACA inhabiting India, China, and other parts of Asia. The species is used extensively in biomedical research and adapts very well to living with humans.Vaccinia virus: The type species of ORTHOPOXVIRUS, related to COWPOX VIRUS, but whose true origin is unknown. It has been used as a live vaccine against SMALLPOX. It is also used as a vector for inserting foreign DNA into animals. Rabbitpox virus is a subspecies of VACCINIA VIRUS.T-Lymphocytes, Cytotoxic: Immunized T-lymphocytes which can directly destroy appropriate target cells. These cytotoxic lymphocytes may be generated in vitro in mixed lymphocyte cultures (MLC), in vivo during a graft-versus-host (GVH) reaction, or after immunization with an allograft, tumor cell or virally transformed or chemically modified target cell. The lytic phenomenon is sometimes referred to as cell-mediated lympholysis (CML). These CD8-positive cells are distinct from NATURAL KILLER CELLS and NATURAL KILLER T-CELLS. There are two effector phenotypes: TC1 and TC2.Hemagglutinin Glycoproteins, Influenza Virus: Membrane glycoproteins from influenza viruses which are involved in hemagglutination, virus attachment, and envelope fusion. Fourteen distinct subtypes of HA glycoproteins and nine of NA glycoproteins have been identified from INFLUENZA A VIRUS; no subtypes have been identified for Influenza B or Influenza C viruses.
Two more vaccines were introduced in between 2014 and 2015 ; Inactivated poliomyelitis vaccine (IPV) and Pneumococcal conjugate ... One percent of children in Nepal have not yet received any of the vaccine coverage. The Community-Based Integrated Management ... The government has provided all vaccines and immunization related logistics without any cost to hospitals, the private ... vaccine (PCV). Six districts of Nepal are declared with 99.9% immunization coverage. Nepal has achieved polio free status in 27 ...
用肺炎球菌聯合疫苗(英語:Pneumococcal conjugate vaccine)(PCV)--一種能預防這種病原中七種常見血清的疫苗--對肺炎鏈球菌進行常規預防接種,能大大降低肺炎球菌性腦膜炎的發病率。[43][50]能涵蓋23株球菌的肺炎球菌多 ... Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. N Engl J Med. 2009, 360 (3): 244-256. PMID 19144940. doi: ... Pneumococcal polysaccharide vaccine)(PPSV)只用於某些群體,(
Pneumococcal conjugate vaccines (PCV) in early infancy, decreases the risk of acute otitis media in healthy infants. PCV is ... "Pneumococcal conjugate vaccines for preventing otitis media". The Cochrane Database of Systematic Reviews (4): CD001480. doi: ... changes in pathogenicity following widespread use of pneumococcal conjugate vaccine". Otolaryngology--Head and Neck Surgery: ... Influenza vaccine is recommended annually for all children. PCV does not appear to decrease the risk of otitis media when given ...
Dagan, R (2009). "Impact of pneumococcal conjugate vaccine on infections caused by antibiotic-resistant Streptococcus ... Visser, A; Hoosen, A (2012). "Haemophilus influenzae type b conjugate vaccines - a South African perspective". Vaccine. 30 ... Vaccines are usually imperfect however, so the effectiveness, E, of a vaccine must be accounted for: V. c. =. 1. −. 1. R. 0. E ... "Oxford Vaccine Group, University of Oxford. Retrieved 12 December 2017.. *^ a b c d e f Somerville, M.; Kumaran, K.; Anderson, ...
"Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine ... Previous pneumococcal polysaccharide vaccine impacts immune response to subsequent pneumococcal conjugate vaccine in the ... "Phase 1 trial of a 13-valent pneumococcal conjugate vaccine in healthy adults". Vaccine. 25 (33): 6164-6. doi:10.1016/j.vaccine ... Vaccine-type and non-vaccine type pneumococci after administration of 9valent CRM 197 conjugate pneumococcal vaccine (Pnc CRM9 ...
"Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine ... 2008). Pneumococcal vaccines: the impact of conjugate vaccine. Washington, DC: ASM Press. ISBN 9781555814083. George Siber's ... a pneumococcal vaccine, Acel-Imune, an acellular pertussis vaccine, Meningitec, a meningococcal meningitis vaccine, Rotashield ... 11/644,924 - Multivalent Pneumococcal Polysaccharide-Protein Conjugate Composition "Vaccine Technology Takes Center Stage in ...
No increase in HIV-load following immunization with conjugate pneumococcal vaccine, Pneumovax, or Typhim-Vi. Proceedings of ... Although conjugate vaccines are the preferred meningococcal vaccine in adolescents 11 years of age or older, polysaccharide ... Although conjugate vaccines are the preferred meningococcal vaccine in adults 55 years of age or younger, polysaccharide ... Vaccines are currently available against all six strains, including the newest vaccine against serogroup B. The first vaccine ...
2009). "Effect of pneumococcal conjugate vaccine on pneumococcal meningitis". N Engl J Med. 360 (3): 244-256. doi:10.1056/ ... Routine vaccination against Streptococcus pneumoniae with the pneumococcal conjugate vaccine (PCV), which is active against ... The introduction of pneumococcal vaccine has lowered rates of pneumococcal meningitis in both children and adults. Recent skull ... A quadrivalent vaccine now exists, which combines four vaccines with the exception of B; immunization with this ACW135Y vaccine ...
"New Vaccine that would be used in Indradhanush Program". "Shri J P Nadda launches Pneumococcal Conjugate Vaccine (PCV) under ... The mission includes five new vaccines, inactivated polio vaccine, adult Japanese Encephalitis vaccine, Rotavirus vaccine, PCV ... In 2017, pneumonia was added to the Mission by incorporating Pneumococcal conjugate vaccine under Universal Immunization ... It aims to immunize all children under the age of 2 years, as well as all pregnant women, against seven vaccine preventable ...
"WHO , Pneumococcal conjugate vaccines". www.who.int. Retrieved 2018-01-16. "Pneumococcal Disease , Vaccines - PCV13 and PPSV23 ... "Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and X-ray defined pneumonia in ... May 2003). "Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine". N. ... pneumococcal conjugate vaccine). Vaccinating children against Streptococcus pneumoniae has led to a decreased rate of these ...
For example, in Gambia, provision of the pneumococcal conjugate vaccine costs $670 per DALY saved. This number can then be ... Kim, SY; Lee, G; Goldie, SJ (Sep 3, 2010). "Economic evaluation of pneumococcal conjugate vaccination in The Gambia". BMC ...
"Pneumococcal conjugate vaccines for preventing otitis media". Cochrane Database Syst Rev (2): CD001480. doi:10.1002/14651858. ...
"Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine". N. Engl. J. Med. ... "Vaccines for preventing pneumococcal infection in adults". Cochrane database of systematic reviews (broj 1): str. CD000422. ... WHO (1999). "Pneumococcal vaccines. WHO position paper". Wkly. Epidemiol. Rec. svezak 74 (broj 23): str. 177.-183. PMID ... "Vaccines for preventing influenza in healthy adults". Cochrane database of systematic reviews (broj 7): str. CD001269. PMID ...
13-valent conjugate pneumococcal vaccine) is a vaccine for the prevention of invasive pneumococcal infections. The introduction ... The company has also pledged to provide up to 740 million doses of its anti-pneumococcal vaccine at discounted rates to infants ... of the original, 7-valent version of the vaccine in 1999 led to a 75% reduction in the incidence of invasive pneumococcal ... An improved version of the vaccine, providing coverage of 13 bacterial variants, was introduced in early 2010. As of 2012 the ...
... including injectable polio vaccine, an adult vaccine against Japanese Encephalitis and Pneumococcal Conjugate Vaccine. Vaccines ... Vaccine-preventable diseases World Immunization Week "Shri J P Nadda launches Pneumococcal Conjugate Vaccine (PCV) under ... and Pneumococcal diseases (Pneumococcal Pneumonia and Meningitis). Hepatitis B and Pneumococcal diseases was added to the UIP ... rotavirus vaccine (RVV) ,Measles-Rubella vaccine (MR). Four new vaccines have been introduced into the country's Universal ...
This vaccine protects from more than 90 types of pneumococcal bacteria. The pneumococcal conjugate vaccine (PCV13 or Prevnar13 ... Pneumococcal Vaccine Side Effects Pneumococcal Side Effects Pneumococcal Treatment CDC Polio Polio vaccine Polio Vaccine Side ... The Meningococcal Conjugate Vaccine (MCV4) is given between the ages of 11 and 12 years of age. As many as half the people who ... This vaccine is a 2 or 3 dose series, depending on the brand of the vaccine, that is given at 2 and 4 months in the 2 dose ...
RVF successfully introduced the pneumococcal conjugate vaccine in the West Bank and Gaza, so that all newborns in both ... "Pneumococcal Vaccination Program in the West Bank and Gaza Sustained - Rostropovich Vishnevskaya Foundations". rostropovich.org ... "RVF Announces Introduction of the Rotavirus Vaccine in the West Bank and Gaza , Rostropovich Vishnevskaya Foundations". ... "Gavi, the Vaccine Alliance" (PDF). gavialliance.org. http://www.euro.who.int/mediacentre/PR/2006/20060222_1 http://www.fas.usda ...
Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine (Report). Centers for Disease ... Vaccines - a Biography edited by Andrew W. Artenstein ISBN 978-1-4419-1107-0[page needed] Gal, O.; Wolfe, C. "Empiricism and ... He then derived a vaccine by altering the infectious agent so as to make it harmless and then introducing this inactivated form ... Several different adjuvants have been used in vaccine preparation. Adjuvants are also used in other ways in researching the ...
The pneumococcal conjugate vaccine, the rotavirus vaccine and the Hepatitis A vaccine are yet to be introduced to the National ... "Cost-effectiveness analysis of the introduction of the pneumococcal conjugate vaccine (PCV-13) in the Egyptian national ... raising funds to provide children from low socioeconomic classes in Egypt with 30,000 doses of Pneumococcal Conjugate Vaccine, ... Southern Vaccine Advocacy Challenge (2011-2012), Grand Challenges Canada: A grant that was given to 5 non-profits around the ...
The conjugate vaccine technique Anderson and his colleagues developed led to a Streptococcus pneumoniae (pneumococcus) vaccine ... Anderson continues to perform research on the development of an inexpensive pneumococcal vaccine for third world countries with ... After moving to the University of Rochester they developed a polysaccharide conjugate vaccine that worked in infants, too. This ... He continues to volunteer his time toward the development of affordable vaccines for pneumococcal diseases. Anderson has played ...
The GAVI Alliance and the Bill & Melinda Gates Foundation are funding two pneumococcal conjugate vaccine (PCV) impact studies ... measuring the impact on disease burden of pneumococcal conjugate vaccine use in Kenya and The Gambia, and evaluating the value ... These projects will estimate the change in incidence of vaccine-type invasive pneumococcal disease (IPD), change in incidence ... These studies, funded through the Pneumococcal Vaccines Accelerated Development and Introduction Plan (PneumoADIP), a project ...
People with A-T who are less than two years old should receive three (3) doses of a pneumococcal conjugate vaccine (Prevnar) ... the 23-valent pneumococcal vaccine should be administered. Immunization with the 23-valent pneumococcal vaccine should be ... 23-valent pneumococcal polysaccharide) vaccines. For the most part, the pattern of immunodeficiency seen in an A-T patient ... influenza and pneumococcal vaccines given to eligible individuals, and sinopulmonary infections treated aggressively to limit ...
... he conducted the economic evaluation of a pneumococcal 7-valent conjugate vaccine for the national immunization list for Turkey ...
Prevnar is the only pneumococcal conjugate vaccine for infants and children which protects against pneumococcal disease like ... Guard Cat Vaccines Fel-O-Vax Cat Vaccines Fluvac Innovator Horse Vaccine GiardiaVax Dog Vaccine Ketaset LeptoVax Dog Vaccine ... Horse Vaccine Pneumobort Horse Vaccine Polyflex Poulvac Poultry Vaccines Presponse Cattle Vaccines ProHeart 6/ProHeart SR-12 ( ... conjugated estrogens) indicated to treat vaginal dryness at menopause Prevnar ; vaccine to protect children from pneumococcal ...
2009). "Effect of pneumococcal conjugate vaccine on pneumococcal meningitis". N Engl J Med. 360 (3): 244-256. doi:10.1056/ ... Weisfelt M, de Gans J, van der Poll T, van de Beek D (2006). "Pneumococcal meningitis in adults: new approaches to management ... ଟିକା(Haemophilus influenzae type B vaccine) ଦେବା ପରେ ଏହି ରୋଗ ବହୁତ କମିଯାଇଛି । ... "Can we prevent cochlear implant recipients from developing pneumococcal meningitis?" (PDF). Clin. Infect. Dis. 46 (1): e1-7. ...
... as the decrease of occult pneumonia after vaccination of children with a pneumococcal vaccine suggests. Infiltration commonly ... highly febrile children with leukocytosis before and after universal conjugate pneumococcal vaccination". Pediatric Emergency ...
CDC: Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with ... CDC: Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with ...
cause pneumococcal disease.. Infants and young children usual y need 4 doses of pneumococcal conjugate vaccine, at 2, 4, 6, and ... Pneumococcal conjugate vaccine (PCV13) can conditions if they did not already receive PCV13.. prevent pneumococcal disease.. ... Many Vaccine Information Statements are available in Spanish and other languages. Pneumococcal Conjugate Vaccine See www. ... to an earlier pneumococcal conjugate Meningitis (infection of the tissue covering the vaccine known as PCV7, or to any vaccine ...
Pneumococcal conjugate vaccine (PCV13) can prevent pneumococcal disease.. Pneumococcal disease refers to any illness caused by ... to an earlier pneumococcal conjugate vaccine known as PCV7, or to any vaccine containing diphtheria toxoid (for example, DTaP ... Infants and young children usually need 4 doses of pneumococcal conjugate vaccine, at 2, 4, 6, and 12-15 months of age. In some ... Tell your vaccine provider if the person getting the vaccine:. *Has had an allergic reaction after a previous dose of PCV13, ...
Pneumococcal Conjugate Vaccine (PCV13): learn about side effects, dosage, special precautions, and more on MedlinePlus ... Pneumococcal conjugate vaccine (called PCV13) protects against 13 types of pneumococcal bacteria. ... Pneumococcal Conjugate Vaccine (PCV13) Information Statement. U.S. Department of Health and Human Services/Centers for Disease ... Anyone who has ever had a life-threatening allergic reaction to a dose of this vaccine, to an earlier pneumococcal vaccine ...
KudoZ) English to Polish translation of Pneumococcal NTHi-protein D Conjugate Vaccine [szczepionki - Medical: Pharmaceuticals ( ... Pneumococcal NTHi-protein D Conjugate Vaccine. Zupełnie nie moja działka, ale próbuję pomóc znajomej. To nazwa szczepionki. ... Pneumococcal NTHi-protein D Conjugate Vaccine. Polish translation: szczepionka przeciwko pneumokokom skoniugowana z białkiem D ... pneumococcal nthi-protein d conjugate vaccine. szczepionka przeciwko pneumokokom skoniugowana z białkiem D NTHi ...
Expert Rev Vaccines. 2009 Aug;8(8):977-86. doi: 10.1586/erv.09.68. Review ... An investigational 13-valent pneumococcal conjugate vaccine (PCV-13) uses CRM(197) as a carrier, similar to the current PCV-7, ... The introduction of a 7-valent pneumococcal conjugate vaccine (PCV-7) into the routine childhood vaccination schedule has been ... Current knowledge regarding the investigational 13-valent pneumococcal conjugate vaccine.. Dinleyici EC1, Yargic ZA. ...
Invasive Pneumococcal Disease After Implementation of 13-Valent Conjugate Vaccine. Pui-Ying Iroh Tam, Lawrence C. Madoff, ... Invasive Pneumococcal Disease After Implementation of 13-Valent Conjugate Vaccine Message Subject (Your Name) has sent you a ... Invasive Pneumococcal Disease After Implementation of 13-Valent Conjugate Vaccine. Pui-Ying Iroh Tam, Lawrence C. Madoff, ... in children caused by nonvaccine types in the era of 13-valent pneumococcal conjugate vaccine (PCV13). ...
... www.cdc.gov/vaccines/hcp/vis/vis-statements/pcv13.html ... Pneumococcal conjugate vaccine (PCV13). www.cdc.gov/vaccines/ ... Pneumococcal conjugate vaccine (PCV13) can prevent pneumococcal disease.. Pneumococcal disease refers to any illness caused by ... to an earlier pneumococcal conjugate vaccine known as PCV7, or to any vaccine containing diphtheria toxoid (for example, DTaP ... Infants and young children usually need 4 doses of pneumococcal conjugate vaccine, at 2, 4, 6, and 12 to 15 months of age. In ...
2008)‎. Incidence of pneumonia is not reduced by pneumococcal conjugate vaccine. Bulletin of the World Health Organization, 86 ...
Professional guide for Pneumococcal Conjugate Vaccine (13-Valent). Includes: pharmacology, pharmacokinetics, contraindications ... Note: Which vaccines are indicated (pneumococcal conjugate vaccine [PCV13] and/or pneumococcal polysaccharide vaccine [PPSV23 ... Pneumococcal Conjugate Vaccine (13-Valent). *Pneumococcal 13-valent vaccine, diphtheria conjugate Intramuscular (Advanced ... Asplenia: Use of pneumococcal conjugate vaccine does not replace use of the 23-valent pneumococcal polysaccharide vaccine in ...
Pneumococcal 13-valent vaccine is used to prevent infection caused by pneumococcal bacteria. This vaccine... ... Pneumococcal bacteria can infect the sinuses and inner ear. It can also infect the lungs, blood, and brain, and these ... Pneumococcal disease is a serious infection caused by a bacteria. ... What is pneumococcal 13-valent conjugate vaccine?. Pneumococcal disease is a serious infection caused by a bacteria. ...
Pneumococcal Conjugate Vaccine and Clinically Suspected Invasive Pneumococcal Disease. Arto A. Palmu, Terhi M. Kilpi, Hanna ... Pneumococcal Conjugate Vaccine and Clinically Suspected Invasive Pneumococcal Disease. Arto A. Palmu, Terhi M. Kilpi, Hanna ... invasive pneumococcal disease. PCV - pneumococcal conjugate vaccine. THL - National Institute for Health and Welfare of Finland ... Pneumococcal Conjugate Vaccine and Clinically Suspected Invasive Pneumococcal Disease. Arto A. Palmu, Terhi M. Kilpi, Hanna ...
Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine.. Pilishvili T1, Lexau C, Farley MM, ... Changes in invasive pneumococcal disease (IPD) incidence were evaluated after 7 years of 7-valent pneumococcal conjugate ... and assessed potential serotype coverage of new conjugate vaccine formulations.. RESULTS: Overall and PCV7-type IPD incidence ... and the 6 additional serotypes included in an investigational 13-valent conjugate vaccine caused 63% of IPD cases among ...
The first conjugate vaccine licensed in this country was the Haemophilus influenzae type b (Hib) vaccine. Hib vaccines have ... The first conjugate vaccine licensed in this country was the Haemophilus influenzae type b (Hib) vaccine. Hib vaccines have ... Efficacy of heptavalent conjugate pneumococcal vaccine (Wyeth Lederle) in 37,000 infants and children: impact on pneumonia, ... Efficacy of heptavalent conjugate pneumococcal vaccine (Wyeth Lederle) in 37,000 infants and children: impact on pneumonia, ...
Receive valent pneumococcal conjugated vaccine in HIV - infected children. Biological: valent pneumococcal conjugated vaccine ... Receive valent pneumococcal conjugated vaccine in HIV negative children. Biological: valent pneumococcal conjugated vaccine ... The immunogenicity and safety of pneumococcal conjugate vaccine in human immunodeficiency virus-infected Thai children. Vaccine ... Pneumococcal conjugate vaccine. HIV infected children. objective of this study is to assess the safety and immunogenicity of a ...
Pneumococcal conjugate vaccine is a vaccine used to protect infants and young children against disease caused by the bacterium ... including the use of pneumococcal conjugate vaccine (Prevnar), pneumococcal polysaccharide vaccine, and antibiotic prophylaxis ... "Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine". JAMA. 295 (14): ... "Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control ...
Pneumococcal 13-valent diphtheria conjugate vaccine is an active immunizing agent used to prevent infection by pneumococcal ... Pneumococcal infection can cause serious problems, such as pneumonia, which affects the lungs; meningitis, which affects the ... For infants and young children, immunization requires 1 to 4 doses of the vaccine, depending on the age at the first dose. This ... This vaccine is to be given only by or under the supervision of your doctor. ...
Pneumococcal conjugate vaccine (PCV) is a pneumococcal vaccine and a conjugate vaccine used to protect infants, young children ... World Health Organization: Pneumococcal vaccines Pneumococcal conjugate vaccine at Curlie (based on DMOZ). ... Streptococcus pneumoniae Pneumonia PneumoADIP Pneumococcal polysaccharide vaccine "Pneumococcal 7-valent Conjugate Vaccine ( ... including the use of pneumococcal conjugate vaccine (Prevnar), pneumococcal polysaccharide vaccine, and antibiotic prophylaxis ...
Many Vaccine Information Statements are available in Spanish and other languages. See www.immunize.org/vis ... You Must Provide Patients with Vaccine Information Statements (VISs) Its Federal Law!. Explains why it is necessary to always ...
To evaluate the impact of the introduction of the heptavalent pneumococcal conjugate vacc ... Impact of the Pneumococcal Conjugate Vaccine in the Management of Highly Febrile Children Aged 6 to 24 Months in an Emergency ... Impact of the Pneumococcal Conjugate Vaccine in the Management of Highly Febrile Children Aged 6 to 24 Months in an Emergency ... To evaluate the impact of the introduction of the heptavalent pneumococcal conjugate vaccine (PCV-7) in the management of ...
Preliminary evidence from large scale field trials indicates that pneumococcal conjugate vaccines are effective in reducing ... efficacy against invasive pneumococcal disease caused by serotypes included in the vaccine in fully or partially vaccinated ... Conjugate vaccines: The current pneumococcal polysaccharide vaccine is ineffective in children ,2 years old and may not produce ... Efficacy of pneumococcal conjugate vaccines in large scale field trials Pediatr Infect Dis J. 2000 Apr;19(4):394-7. doi: ...
Pneumococcal conjugate vaccine (PCV) is a highly effective intervention to reduce invasive pneumococcal disease and pneumonia. ... ZAR, Heather J and MADHI, Shabir A. Pneumococcal conjugate vaccine - a health priority. SAMJ, S. Afr. med. j. [online]. 2008, ... Consequently, vaccine-preventable invasive disease is almost 60 times higher in HIV-infected compared to -uninfected children, ... Studies evaluating a 9-valent PCV in South Africa and The Gambia reported a 72 - 77% reduction in vaccine-serotype-specific ...
Biological: 13 valent pneumococcal conjugate vaccine with Polysorbate 80 Biological: 13 valent pneumococcal conjugate vaccine ... Drug Information available for: Polysorbate 80 Heptavalent pneumococcal conjugate vaccine Pneumococcal Vaccines ... 13 valent pneumococcal conjugate vaccine with Polysorbate 80 Active Comparator: 2 Biological: 13 valent pneumococcal conjugate ... Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants. This study has been completed. ...
60 years old receiving 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine; evaluate the ... NYSE: PFE) announced today the initiation of a Phase 3 program for its 20-Valent pneumococcal conjugate vaccine (20vPnC) ... Pfizer Initiates Phase 3 Program for 20-Valent Pneumococcal Conjugate Vaccine for the Prevention of Invasive Disease and ... Pfizer (PFE) Commences Phase 3 Program for 20-Valent Pneumococcal Conjugate Vaccine (20vPnC) Candidate, PF-06482077. December ...
  • The current preparation is Synforix PCV10, which is given intramuscularly with the pentavalent vaccine in EPI schedule. (banglajol.info)